Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.82 USD | +0.61% | +0.48% | 0.00% |
Jun. 05 | ArriVent, Alphamab Unit to Collaborate on Antibody Drug Conjugates For Cancer Treatment | MT |
Jun. 05 | Alphamab Strikes Deal with Nasdaq-Listed ArriVent to Co-Develop Antibody Drug Conjugates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 625M | |
+50.81% | 56.87B | |
+37.15% | 39.72B | |
-5.93% | 39.27B | |
-6.90% | 28.73B | |
+13.10% | 26.21B | |
-15.78% | 19.79B | |
+31.47% | 12.28B | |
+28.12% | 12.23B | |
+0.58% | 12.12B |
- Stock Market
- Equities
- AVBP Stock
- News ArriVent BioPharma, Inc.
- LifeSci Capital Starts ArriVent BioPharma With Outperform Rating, $33 Price Target